KRAS strikes back
First-in-human trial initiations reveal four KRAS assets.
Regor’s selective approach attracts Roche
For $850m up front Roche gets to challenge Pfizer.
PD-1 drugs set to have their stomach cancer wings clipped
A US adcom strongly recommends restricting Keytruda, Opdivo and Tevimbra use to PD-L1 expressers.
OncoC4 creates a bispecific buzz
But the reasons for its all-stock acquisition of AcroImmune seem more prosaic.
